Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880533 | 1.00 | USP2 (0.49) | USP2MAPTTHRBALOX15HIF1A | |
| SCHEMBL10608422 | 0.91 | SLC7A5 (0.50) | USP2MAPTTHRBALOX15HIF1A | |
| SCHEMBL296690 | 0.91 | SLC7A5 (0.50) | USP2MAPTTHRBALOX15HIF1A | |
| SCHEMBL38374 | 0.91 | SLC7A5 (0.50) | USP2MAPTTHRBALOX15HIF1A | |
| Bromide SCHEMBL10477399 | 0.90 | SLC7A5 (0.49) | USP2MAPTTHRBALOX15HIF1A | |
| Bromide SCHEMBL10477401 | 0.90 | SLC7A5 (0.49) | USP2MAPTTHRBALOX15HIF1A | |
| Hydrochloric Acid SCHEMBL10477430 | 0.90 | SLC7A5 (0.49) | USP2MAPTTHRBALOX15HIF1A | |
| Hydrochloric Acid SCHEMBL10421601 | 0.90 | SLC7A5 (0.49) | USP2MAPTTHRBALOX15HIF1A | |
| SCHEMBL13957561 | 0.84 | USP2 (0.46) | USP2MAPTTHRBALOX15HIF1A | |
| SCHEMBL29141120 | 0.84 | USP2 (0.46) | USP2MAPTTHRBALOX15HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241306-A2 | Compound with antioxidant peptides | Henkel AG & Co. KGaA (DE) | 2010-10-20 | — | — | EP | claimed |
| WO-2004021981-A2 | METHODS FOR THE PREPARATION OF β-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20030113882-A1 | Methods for the preparation of beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-19 | — | — | US | claimed |
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240156892-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050158373-A1 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| WO-2005001023-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004070054-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004021981-A2 | METHODS FOR THE PREPARATION OF β-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | disclosed |
| US-20040029796-A1 | Medicinal uses of mu-opioid receptor agonists | CORNELL RESEARCH FOUNDATION, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030113882-A1 | Methods for the preparation of beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-19 | — | — | US | disclosed |
| EP-1303186-A2 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002005748-A2 | MEDICINAL USES OF MU-OPIOID RECEPTOR AGONISTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | USP2 4135/4885MAPT 1279/4885THRB 1758/4885 |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | USP2 3566/4885MAPT 1274/4885THRB 2388/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | USP2 2999/4885MAPT 734/4885THRB 2862/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | USP2 2234/4885MAPT 1390/4885THRB 3090/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | USP2 3048/4885MAPT 35/4885THRB 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.